🔗 Share this article

As the United States undertakes unprecedented adjustments to its immunization guidelines, one figure has surfaced somewhat surprisingly: Høeg, a Danish American sports physician and epidemiologist who first made her name by questioning Covid vaccines throughout the global health crisis and has zeroed in on possible deaths after Covid immunization in her short time at the FDA.

Scheduled Overhauls to Pediatric Immunization Schedule

Public health authorities were set to unveil major revisions to the pediatric vaccination calendar earlier this month, aligning the US with the Danish vaccine program, sources say – a major change that would put the US out of alignment with many the global community with little proof for public health gain. The planned update has been delayed until the coming year.

Rather than Vinay Prasad, Høeg is listed to speak at the event. She was recently named temporary leader of the FDA’s drug evaluation center, the fifth person to lead the office this year.

A Shift at the FDA

This interim role might represent a closer partnership between the pharmaceutical and biologics divisions as Dr. Høeg and Prasad strengthen their influence at the FDA – and it suggests a greater focus upon rolling back long-standing vaccines at the FDA.

Høeg has often pushed for ending specific childhood shot schedules in the US to become more like Denmark, a country with universal health coverage and a citizenry about the size of the state of Wisconsin.

To date statements, she has persisted in emphasizing on vaccination policy – usually the domain of Dr. Prasad, director of the FDA’s CBER – as opposed to medication approval.

Questions Over Background

The appointee has no obvious experience in medication creation, oversight or management, which has been standard for former directors of the CBER. She has served at the FDA as a top consultant to the FDA chief and the vaccine center since spring.

“She appears not to have the requisite experience” for overseeing the CDER, remarked Jonathan Howard. “She has not conducted a scientific study. She has no expertise in leading a sizeable institution. She has no expertise in industry regulation.”

Former directors of the center would “be deeply familiar with legal statutes and the research of medication creation”, noted a former acting FDA commissioner. “Frankly, she lacks the type of experience that previous people who led CBER have had.”

This division has an immense workload at the FDA, Woodcock pointed out.

“The public just zeroes in on the new drug program, but the generic program approves a multitude of generic drugs. There is also a biosimilars program, over-the-counter program and more, and all of those have to be managed,” Dr. Woodcock said. “The thing you neglect, that is the part that I always told people is going to cause problems.”

Furthermore, a substantial leadership element to the position, which oversees more than 5,000 personnel. “It’s a massive management job, if you do it right,” she said.

Agency Reaction and Contentious Initiatives

Regarding inquiries about Høeg’s fitness for the role and whether this assignment represents greater collaboration among FDA leaders on immunizations, a spokesperson said that the “concerns are based on flawed assumptions”.

“This background matches the functions of her position,” the representative stated, citing the months Dr. Høeg spent counseling the FDA commissioner on “drug safety and oversight research, including computerized risk analysis and shot safety tracking”.

In her interim role, Dr. Høeg inherits the commissioner’s recently launched expedited review system, a controversial one-day drug-approval program that reportedly troubled her preceding directors. “By what process are these medications being picked for this voucher program? Who takes the decisions?” Dr. Howard asked. “There is a lot of confidentiality happening at the agency right now.”

In general, he remarked, “the agency seems to be moving towards laxer oversight of all drugs, aside from immunizations.”

Established History on Vaccines

With vaccines, Dr. Høeg has a more established, if problematic, track record, critics observe. She released a study using unconfirmed volunteer-provided data to assess the rate of myocarditis after COVID-19 vaccination. She advised the state of Florida chief medical officer Joseph Ladapo, who was said to have changed statistics to imply COVID-19 vaccines are pose a greater threat than they are.

Included in her “desired changes” for the current federal leadership included altering rules for novel immunizations and ending “optional” vaccines, she said following the vote on a audio program. At the FDA, Høeg has allegedly suggested barring young men from getting Covid vaccinations.

“She is an thorough true believer who begins with her preconceived notions and reverse-engineers to fit the evidence in a highly misleading, dishonest way,” Dr. Howard said.

Gaining Influence and a “Revenge Tour”

Høeg became part of fellow dissenters, {like|